XAn interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules

Cell

Volumn 154, Issue 5, 2013, Pages

  Basu, Amrita ^a   Bodycombe, Nicole E ^a   Cheah, Jaime H ^a   Price, Edmund V ^a   Liu, Ke ^a   Schaefer, Giannina I ^a   Ebright, Richard Y ^a   Stewart, Michelle L ^a   Ito, Daisuke ^a,d   Wang, Stephanie ^a   Bracha, Abigail L ^a   Liefeld, Ted ^a   Wawer, Mathias ^a   Gilbert, Joshua C ^a   Wilson, Andrew J ^b   Stransky, Nicolas ^a,e   Kryukov, Gregory V ^a   Dancik, Vlado ^a   Barretina, Jordi ^a,f   Garraway, Levi A ^a   Hon, C Suk Yee ^a   Munoz, Benito ^a   Bittker, Joshua A ^a   Stockwell, Brent R ^c   Khabele, Dineo ^b   Stern, Andrew M ^a   Clemons, Paul A ^a   Shamji, Alykhan F ^a   Schreiber, Stuart L ^a   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d EISAI INC   (United States)

^e Blueprint Medicines   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; ANTINEOPLASTIC AGENT; BETA CATENIN; BRD 63610; CALCINEURIN; CYCLIN D1; CYCLOSPORIN A; DAPORINAD; GALLOCATECHIN; GMX 1778; K RAS PROTEIN; NAVITOCLAX; NERATINIB; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN MCL 1; PROTEIN P53; RAPAMYCIN; SCATTER FACTOR; SELUMETINIB; SULFORHODAMINE B; TACROLIMUS; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CANCER PATIENT; CELL LINEAGE; COLON CANCER; COPY NUMBER VARIATION; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; MOLECULE; NEOPLASM; NONHUMAN; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR GENE;

EID: 84883319024     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2013.08.003     Document Type: Article

References (52)

1. J.C. Acosta, A. O'Loghlen, A. Banito, M.V. Guijarro, A. Augert, S. Raguz, M. Fumagalli, M. Da Costa, C. Brown, and N. Popov Chemokine signaling via the CXCR2 receptor reinforces senescence Cell 133 2008 1006 1018
2. C.L. Arteaga EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans Cancer Cell 9 2006 421 423
3. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehár, G.V. Kryukov, and D. Sonkin The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
4. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: A practical and powerful approach to multiple testing J. R. Statist. Soc. B 57 1995 289 300
5. C.N. Bennett, S.E. Ross, K.A. Longo, L. Bajnok, N. Hemati, K.W. Johnson, S.D. Harrison, and O.A. MacDougald Regulation of Wnt signaling during adipogenesis J. Biol. Chem. 277 2002 30998 31004
6. E.J. Brown, P.A. Beal, C.T. Keith, J. Chen, T.B. Shin, and S.L. Schreiber Control of p70 s6 kinase by kinase activity of FRAP in vivo Nature 377 1995 441 446
7. Z. Chen, K. Cheng, Z. Walton, Y. Wang, H. Ebi, T. Shimamura, Y. Liu, T. Tupper, J. Ouyang, and J. Li A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 483 2012 613 617
8. H.W. Cheung, G.S. Cowley, B.A. Weir, J.S. Boehm, S. Rusin, J.A. Scott, A. East, L.D. Ali, P.H. Lizotte, and T.C. Wong Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer Proc. Natl. Acad. Sci. USA 108 2011 12372 12377
9. R.B. Corcoran, J. Settleman, and J.A. Engelman Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers Oncotarget 2 2011 336 346
10. R.B. Corcoran, K.A. Cheng, A.N. Hata, A.C. Faber, H. Ebi, E.M. Coffee, P. Greninger, R.D. Brown, J.T. Godfrey, and T.J. Cohoon Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23 2013 121 128
11. T. Cormen, F. Dehne, P. Fraigniaud, and Y. Matias Guest editors' foreword Theor. Comput. Syst. 33 2000 335-335
12. S.J. Dixon, K.M. Lemberg, M.R. Lamprecht, R. Skouta, E.M. Zaitsev, C.E. Gleason, D.N. Patel, A.J. Bauer, A.M. Cantley, and W.S. Yang Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 149 2012 1060 1072
13. L. Gandhi, D.R. Camidge, M. Ribeiro de Oliveira, P. Bonomi, D. Gandara, D. Khaira, C.L. Hann, E.M. McKeegan, E. Litvinovich, and P.M. Hemken Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors J. Clin. Oncol. 29 2011 909 916
14. M.J. Garnett, E.J. Edelman, S.J. Heidorn, C.D. Greenman, A. Dastur, K.W. Lau, P. Greninger, I.R. Thompson, X. Luo, and J. Soares Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
15. D. Gonzalez de Castro, P.A. Clarke, B. Al-Lazikani, and P. Workman Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance Clin. Pharmacol. Ther. 93 2013 252 259
16. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
17. L.M. Heiser, A. Sadanandam, W.L. Kuo, S.C. Benz, T.C. Goldstein, S. Ng, W.J. Gibb, N.J. Wang, S. Ziyad, and F. Tong Subtype and pathway specific responses to anticancer compounds in breast cancer Proc. Natl. Acad. Sci. USA 109 2012 2724 2729
18. E.H. Jho, T. Zhang, C. Domon, C.K. Joo, J.N. Freund, and F. Costantini Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway Mol. Cell. Biol. 22 2002 1172 1183
19. A. Jiménez-Marín, M. Collado-Romero, M. Ramirez-Boo, C. Arce, and J.J. Garrido Biological pathway analysis by ArrayUnlock and Ingenuity Pathway Analysis BMC Proc. 3 Suppl 4 2009 S6
20. J. Ju, J. Hong, J.N. Zhou, Z. Pan, M. Bose, J. Liao, G.Y. Yang, Y.Y. Liu, Z. Hou, and Y. Lin Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea Cancer Res. 65 2005 10623 10631
21. S. Kaga, L. Zhan, E. Altaf, and N. Maulik Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium J. Mol. Cell. Cardiol. 40 2006 138 147
22. J.E. Larsen, T. Cascone, D.E. Gerber, J.V. Heymach, and J.D. Minna Targeted therapies for lung cancer: clinical experience and novel agents Cancer J. 17 2011 512 527
23. C. Lefebvre, P. Rajbhandari, M.J. Alvarez, P. Bandaru, W.K. Lim, M. Sato, K. Wang, P. Sumazin, M. Kustagi, and B.C. Bisikirska A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers Mol. Syst. Biol. 6 2010 377
24. A. Liberzon, A. Subramanian, R. Pinchback, H. Thorvaldsdóttir, P. Tamayo, and J.P. Mesirov Molecular signatures database (MSigDB) 3.0 Bioinformatics 27 2011 1739 1740
25. J. Liu, J.D. Farmer Jr., W.S. Lane, J. Friedman, I. Weissman, and S.L. Schreiber Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66 1991 807 815
26. J. Luo, M.J. Emanuele, D. Li, C.J. Creighton, M.R. Schlabach, T.F. Westbrook, K.K. Wong, and S.J. Elledge A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
27. U. McDermott, S.V. Sharma, L. Dowell, P. Greninger, C. Montagut, J. Lamb, H. Archibald, R. Raudales, A. Tam, and D. Lee Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling Proc. Natl. Acad. Sci. USA 104 2007 19936 19941
28. H. Pan, J. Cao, and W. Xu Selective histone deacetylase inhibitors Anticancer. Agents Med. Chem. 12 2012 247 270
29. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, D. Zecchin, R.L. Beijersbergen, A. Bardelli, and R. Bernards Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
30. Z.H. Ran, J. Zou, and S.D. Xiao Experimental study on anti-neoplastic activity of epigallocatechin-3-gallate to digestive tract carcinomas Chin. Med. J. (Engl.) 118 2005 1330 1337
31. J. Rosenbluh, D. Nijhawan, A.G. Cox, X. Li, J.T. Neal, E.J. Schafer, T.I. Zack, X. Wang, A. Tsherniak, and A.C. Schinzel β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis Cell 151 2012 1457 1473
32. A. Sartore-Bianchi, F. Di Nicolantonio, M. Nichelatti, F. Molinari, S. De Dosso, P. Saletti, M. Martini, T. Cipani, G. Marrapese, and L. Mazzucchelli Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer PLoS ONE 4 2009 e7287
33. S.V. Sharma, D.A. Haber, and J. Settleman Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat. Rev. Cancer 10 2010 241 253
34. R.H. Shoemaker The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 6 2006 813 823
35. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
36. K.S. Smalley PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma Curr. Opin. Investig. Drugs 11 2010 699 706
37. A.J. Souers, J.D. Leverson, E.R. Boghaert, S.L. Ackler, N.D. Catron, J. Chen, B.D. Dayton, H. Ding, S.H. Enschede, and W.J. Fairbrother ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat. Med. 19 2013 202 208
38. A.B. Sparks, P.J. Morin, B. Vogelstein, and K.W. Kinzler Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer Cancer Res. 58 1998 1130 1134
39. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, J. Du, A. Davis, M.M. Mongare, J. Gould, and D.T. Frederick Tumor micro-environment contributes to innate RAF-inhibitor resistance through HGF secretion Nature 487 2012 500 504
40. S. Sun, J.H. Schiller, M. Spinola, and J.D. Minna New molecularly targeted therapies for lung cancer J. Clin. Invest. 117 2007 2740 2750
41. S.K. Tahir, J. Wass, M.K. Joseph, V. Devanarayan, P. Hessler, H. Zhang, S.W. Elmore, P.E. Kroeger, C. Tse, S.H. Rosenberg, and M.G. Anderson Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines Mol. Cancer Ther. 9 2010 545 557
42. C. Tse, A.R. Shoemaker, J. Adickes, M.G. Anderson, J. Chen, S. Jin, E.F. Johnson, K.C. Marsh, M.J. Mitten, and P. Nimmer ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 68 2008 3421 3428
43. J. Vervoorts, J. Lüscher-Firzlaff, and B. Lüscher The ins and outs of MYC regulation by posttranslational mechanisms J. Biol. Chem. 281 2006 34725 34729
44. Z. Wang, A. Havasi, J.M. Gall, H. Mao, J.H. Schwartz, and S.C. Borkan Beta-catenin promotes survival of renal epithelial cells by inhibiting Bax J. Am. Soc. Nephrol. 20 2009 1919 1928
45. M. Weïwer, J.A. Bittker, T.A. Lewis, K. Shimada, W.S. Yang, L. MacPherson, S. Dandapani, M. Palmer, B.R. Stockwell, S.L. Schreiber, and B. Munoz Development of small-molecule probes that selectively kill cells induced to express mutant RAS Bioorg. Med. Chem. Lett. 22 2012 1822 1826
46. J. Yoon, K.H. Koo, and K.Y. Choi MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy Cancer Res. 71 2011 445 453
47. J. Zhu, and T. Hastie Classification of gene microarrays by penalized logistic regression Biostatistics 5 2004 427 443
48. D.T. Lang, and R. Ihaka The Future of Statistical Computing Comment Technometrics 50 2008 443 446
49. E. Paparoditis, and D.N. Politis Bootstrap hypothesis testing in regression models Stat. Probab. Lett. 74 2005 356 365
50. A.J. Wilson, D. Arango, J.M. Mariadason, B.G. Heerdt, and L.H. Augenlicht TR3/Nur77 in colon cancer cell apoptosis Cancer Res. 63 2003 5401 5407
51. A.J. Wilson, E. Holson, F. Wagner, Y.L. Zhang, D.M. Fass, S.J. Haggarty, S. Bhaskara, S.W. Hiebert, S.L. Schreiber, and D. Khabele The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells Cancer Biol. Ther. 12 2011 484 493
52. H. Zou, and T. Hastie Regularization and variable selection via the elastic net J. R. Stat. Soc. Series B Stat. Methodol. 67 2005 301 320